Independent
Tenure on this board
14.5 yrs
Meeting calendar
RVTY · Annual meeting · Tuesday, April 28, 2026
Revvity Inc
10 nominees · 5 ballot items.
Election of ten directors; Ratification of Deloitte & Touche LLP as independent auditor; Advisory (non-binding) approval of executive compensation; Amendment to By-laws to allow shareholders owning 25% to call a special meeting; Shareholder proposal requiring certain executives to retain 25% of net after-tax shares acquired through equity pay programs (with proponent John Chevedden).
Market cap
$12.5B
1Y TSR
+11.6%
Board grade
C
Record date
Mar 2, 2026
Filing
DEF 14A
Meeting concluded · Apr 28, 2026
Follow how the vote landed and what changed on Revvity Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot5
- 1
Election of Directors
ManagementBoard: FORElect ten nominees to the board for one-year terms.
- 2
Ratification of Selection of Independent Registered Public Accounting Firm
ManagementBoard: FORRatify the audit committee’s selection of Deloitte & Touche LLP as Revvity’s independent registered public accounting firm for fiscal 2026.
- 3
Non-Binding Advisory Vote on Executive Compensation (Say-on-Pay
ManagementBoard: FORAdvisory vote to approve executive compensation as disclosed in the proxy (Compensation Discussion and Analysis and tables).
- 4
Amendment to By-Laws to Allow Shareholders Owning 25% to Call a Special Meeting
ManagementBoard: FORAmend By-laws to lower the ownership threshold to call special shareholder meetings from 40% to 25%.
- 5
Shareholder Proposal Regarding Executives To Retain Significant Stock
Shareholder — John CheveddenBoard: AGAINSTShareholder-submitted proposal (proponent John Chevedden) requesting a policy requiring the five named executive officers to retain 25% of net after-tax shares acquired through equity pay programs until retirement and prohibiting hedging of those shares.
More detail
The shareholder proposal from John Chevedden requests a policy requiring the five named executive officers to retain 25% of net after-tax shares acquired through equity pay programs until retirement and to prohibit hedging of those shares. The proponent argues this would better align executives with long-term shareholder interests in light of stock price decline and operational headwinds, citing specific business challenges and litigation exposure. Management opposes on grounds that existing stock ownership guidelines, clawbacks, hedging prohibitions, and 10b5-1 plans already align interests; that the proposal could hinder recruitment/retention and be administratively burdensome; and that the company’s peer group does not adopt such a retention mandate. The board recommends voting AGAINST.
Director elections
Nominees on the ballot10
Independent
Tenure on this board
10.5 yrs
Also a director at
O-i Glass Inc (OI)Phinia Inc (PHIN)
Independent
Tenure on this board
2.5 yrs
Independent
Tenure on this board
4.0 yrs
Also a director at
Bioventus Inc (BVS)
Independent
Tenure on this board
25.5 yrs
Also a director at
Borgwarner Inc (BWA)Astronova Inc (ALOT)
Not independent
Tenure on this board
6.9 yrs
Also a director at
Amphenol Corp (APH)
Independent
Tenure on this board
2.5 yrs
Also a director at
Idexx Laboratories Inc (IDXX)
Independent
Tenure on this board
6.4 yrs
Also a director at
Zai Lab Ltd (ZLAB)
Independent
Tenure on this board
10.5 yrs
Also a director at
Cerus Corp (CERS)Standard Biotools Inc (LAB)Alamar Biosciences Inc (ALMR)
Independent
Tenure on this board
9.5 yrs
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | T. Rowe Price Investment Management, Inc. | 19.9% | 22,198,422 | $1.9B |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 8.9% | 9,921,128 | $869M |
| 3 | EdgePoint Investment Group Inc. | 7.9% | 8,800,863 | $771M |
| 4 | JANUS HENDERSON GROUP PLC | 7.0% | 7,822,280 | $685M |
| 5 | VANGUARD CAPITAL MANAGEMENT LLC | 6.6% | 7,329,980 | $642M |
| 6 | VANGUARD PORTFOLIO MANAGEMENT LLC | 4.3% | 4,813,167 | $422M |
| 7 | STATE STREET CORP | 3.9% | 4,310,313 | $378M |
| 8 | BlackRock, Inc. | 3.0% | 3,355,603 | $294M |
| 9 | VICTORY CAPITAL MANAGEMENT INC | 2.9% | 3,204,127 | $281M |
| 10 | DIMENSIONAL FUND ADVISORS LP | 2.5% | 2,754,075 | $241M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Revvity Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Apogee Therapeutics IncAPGE
Special meeting·Aug 11, 2026·$10.1B
Jazz Pharmaceuticals PLCJAZZ
Annual meeting·Jul 23, 2026·$15.2B
Amneal Pharmaceuticals IncAMRX
Special meeting·Jul 31, 2026·$5.8B
Doximity IncDOCS
Annual meeting·Aug 27, 2026·$4.1B
Haemonetics CorpHAE
Annual meeting·Jul 24, 2026·$3.6B
Organon & CoOGN
Special meeting·Jul 23, 2026·$3.5B
Reference
Frequently asked questions
- When is the Revvity Inc 2026 annual meeting?
- Revvity Inc (RVTY) holds its 2026 annual shareholder meeting on Tuesday, April 28, 2026.
- What is the record date for the Revvity Inc 2026 meeting?
- The record date for the Revvity Inc 2026 meeting is Monday, March 2, 2026. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Revvity Inc's 2026 meeting?
- The board is presenting 10 director nominees at the Revvity Inc 2026 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Revvity Inc 2026 meeting?
- Shareholders will vote on 5 proposals at the Revvity Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.